NCT03151928

Brief Summary

The validation study is intended to provide comparative data on the diagnosis of vaginal infections as performed in primary care settings versus the diagnosis provided through standard diagnostic testing performed in a reference laboratory. The clinician and lab diagnoses will be compared to those obtained using the BD MAX Vaginal Panel on the BD MAX System.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
299

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 10, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 12, 2017

Completed
2 months until next milestone

Study Start

First participant enrolled

July 6, 2017

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 15, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 15, 2018

Completed
Last Updated

October 4, 2018

Status Verified

October 1, 2018

Enrollment Period

1.1 years

First QC Date

May 10, 2017

Last Update Submit

October 3, 2018

Conditions

Outcome Measures

Primary Outcomes (3)

  • BV Result Agreement

    Comparison of the level of agreement of clinician diagnosed BV to vaginal swab samples evaluated for BV using Nugent's criteria and the BD MAX Vaginal Panel

    enrollment

  • Trichomonas (TV) Result Agreement

    Comparison of the level of agreement of clinician diagnosed TV to the laboratory diagnosis of TV identified by quantitative PCR using the GeneXpert system by Cepheid and the BD MAX Vaginal Panel

    enrollment

  • Yeast Result Agreement

    Comparison of the level of agreement of clinician diagnosed yeast vaginitis to laboratory diagnosis of yeast identified with culture and the BD MAX Vaginal Panel

    enrollment

Secondary Outcomes (2)

  • Patterns of clinician testing

    enrollment

  • Prescribed Treatments

    enrollment

Study Arms (1)

women presenting with vaginitis symptoms

Women with vaginitis seeking routine care will be approached to have five additional swabs collected during their pelvic exam * vaginal swab for qualitative PCR using the BD Max Vaginal Panel on the automated BDMAX System * Vaginal smear for evaluation with Gram's stain and Nuget's criteria * Vaginal swab for yeast culture * Vaginal swab for Trichomonas vaginalis NAAT * Vaginal swab for discrepant analysis testing

Diagnostic Test: BDMax Vaginal Panel

Interventions

BDMax Vaginal PanelDIAGNOSTIC_TEST

The tests will be used to compare results between clinician diagnosis/routine care testing and the above interventions

Also known as: Gram Stain/Nuget Criteria, yeast culture, Trichomonas vaginalis NAAT
women presenting with vaginitis symptoms

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsWomen
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Women presenting to primary care offices with symptoms of vaginitis

You may qualify if:

  • Female, Age 18-40
  • Presenting with symptoms of vaginitis; vaginal discharge, vaginal odor, vulvar or vaginal itch, vulvar or vaginal discomfort (i.e. irritation, burning pain or vulvar edema).
  • Able and willing to provide verbal consent.
  • Willingness to undergo all study-related assessments and procedures, including the collection of multiple vaginal swabs, answer questions related to demographic and health information and follow all other study-related procedures.

You may not qualify if:

  • Women who meet any of the following criteria by participant report will be excluded from the study:
  • ) Any condition that, in the opinion of the Investigator, would preclude provision of consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Magee-Womens Hospital of UPMC/associated community clinics

Pittsburgh, Pennsylvania, 15213, United States

Location

Related Publications (1)

  • Hillier SL, Austin M, Macio I, Meyn LA, Badway D, Beigi R. Diagnosis and Treatment of Vaginal Discharge Syndromes in Community Practice Settings. Clin Infect Dis. 2021 May 4;72(9):1538-1543. doi: 10.1093/cid/ciaa260.

MeSH Terms

Conditions

Vaginitis

Condition Hierarchy (Ancestors)

Vaginal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Sharon L Hillier, PhD

    University of Pittsburgh

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 10, 2017

First Posted

May 12, 2017

Study Start

July 6, 2017

Primary Completion

August 15, 2018

Study Completion

August 15, 2018

Last Updated

October 4, 2018

Record last verified: 2018-10

Data Sharing

IPD Sharing
Will not share

Locations